← ANALYST RATINGS · TIPRANKS
ARS Pharmaceuticals (SPRY): analyst forecast and price target
Analyst consensus
Moderate Buy1 Buy0 Hold0 Sell
Ratings of 1 analysts in the last 3 months · top analysts only12-month forecast
Based on 1 price targets given in the last 3 months, the average target is $30.00, the highest $30.00, the lowest $30.00. The average is +646.3% from the last price of $4.02.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $4.50 → $4.00−11.1% | Hold | −0.5% | Reiterated | 16.09.26on TipRanks 08:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $4.50 → $4.00−11.1% | Hold | −0.5% | Reiterated | 16.09.26on TipRanks 08:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $4.50 → $4.00−11.1% | Hold | −0.5% | Reiterated | 16.09.26on TipRanks 08:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $4.00 | Sell | −0.5% | Reiterated | 16.09.26on TipRanks 08:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $4.50 → $4.00−11.1% | Sell | −0.5% | Downgrade | 16.09.26on TipRanks 08:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $4.50 → $4.00−11.1% | Hold | −0.5% | Reiterated | 16.09.26on TipRanks 08:05 | — | |
| Roanna Ruiz★★★★★★★★★★#9351 · hits 46% · avg −0.3% | Leerink Partners | $18.00 → $15.00−16.7% | Buy | +273.1% | Reiterated | 08.09.26on TipRanks 06:11 | −3.5%next day −2.5% · 5 days −20.0% | ↗ |
| Joshua Schimmer★★★★★★★★★★#407 · hits 51% · avg +19.0% | Cantor Fitzgerald | $30.00 | Buy | +646.3% | Reiterated | 14.08.26on TipRanks 08:55 | −7.2%next day +10.9% · 5 days −1.2% | ↗ |
| Lachlan Hanbury Brown★★★★★★★★★★#11394 · hits 35% · avg −5.4% | William Blair | — | Buy | — | Reiterated | 14.08.26on TipRanks 05:25 | −7.2%next day +10.9% · 5 days −1.2% | ↗ |
| Carl Byrnes★★★★★★★★★★#11765 · hits 37% · avg −4.0% | Northland Securities | $25.00 | Buy | +521.9% | Reiterated | 15.04.26on TipRanks 10:25 | −2.3%next day +1.7% · 5 days +3.1% | ↗ |
| Kyle Bauser★★★★★★★★★★#12304 · hits 37% · avg −14.9% | Roth MKM | $30.00 | Buy | +646.3% | Reiterated | 14.04.26on TipRanks 17:15 | −2.3%next day +1.7% · 5 days +3.1% | ↗ |
| Ryan Deschner★★★★★★★★★★#506 · hits 69% · avg +41.7% | Raymond James | — | Buy | — | Reiterated | 09.01.26on TipRanks 09:45 | +18.6%next day −13.0% · 5 days −18.3% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering ARS Pharmaceuticals
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $22.50 at a price of $4.31 (+422.0%); now: $22.50 at $4.02 (+459.7%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 2 | 2 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 17.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.30 (from $-0.40 to $-0.26). Last quarter: $-0.63.
Sales
Next quarter’s sales estimate — $42M (from $37M to $46M). Last quarter: $34M.
Best top-analyst consensus in the sector · Healthcare
About ARS Pharmaceuticals
- CEO: Donn Casale
- Employees: 195
- 11682 El Camino Real, San Diego, CA, 92130, US
- ars-pharma.com
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.
Data from the stock’s TipRanks forecast page, read 74 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗